Our Approach in Science and Technology:
CardioVascular BioTherapeutics, Inc. (CVBT) is a clinical stage biopharmaceutical company advancing novel therapeutics to address diseases such as diabetic wounds, severe ischemic heart disease and peripheral artery disease. Our pre-clinical therapeutic programs include erectile dysfunction, infarct stroke, degenerative disk disease and Parkinson’s Disease. CVBT is focused on targeted delivery of next generation molecules which will improve the quality of life for those suffering from vascular dysfunction.
In The News
We employ human proteins from the Fibroblast Growth Factor family. Our lead candidate stimulates the growth of new blood vessels when administered to ischemic organs and tissues. These anatomical targets are shown in our pipeline section.
Peter Jennings - ABC World News report on CVBT’s Phase 1 Heart Trial with company doctors